Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Viktoriya Stalbovskaya"'
Autor:
Alessandro M. Vannucchi, Hagop M. Kantarjian, Jean-Jacques Kiladjian, Jason Gotlib, Francisco Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, Victor Sandor, Prashanth Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srdan Verstovsek
Publikováno v:
Haematologica, Vol 100, Iss 9 (2015)
Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies. In addition, ruxolitinib was associated with prolonged survival compared wit
Externí odkaz:
https://doaj.org/article/bc698fc1152a4379840e4851a3e4dbc4
Autor:
Erika Hamilton, Thierry Petit, Barbara Pistilli, Anthony Goncalves, Ana Alexandra Ferreira, Florence Dalenc, Fatima Cardoso, Monica M Mita, Luis Manso, Syed M Karim, Francois-Clement Bidard, Philippe Aftimos, Santiago Escriváa-de-Romaníi, Noemia Afonso, Ernesto Wasserman, Kees Bol, Viktoriya Stalbovskaya, Anastasia Vliet, Anastasia Murat, Mohamed Bekradda, Thomas Bachelot
Publikováno v:
Cancer Research. 82:OT2-15
Background Zenocutuzumab is a humanized bispecific full-length IgG1 antibody targeting both HER2 and HER3 with enhanced ADCC activity. The unique Dock & Block mechanism inhibits HER3 from interacting with its ligands by targeting HER2 at a different
Autor:
Marc Díez García, Antoine Hollebecque, Rocio Garcia-Carbonero, Christiane Jungels, Elisabeth Smyth, Shumei Kato, Guillem Argilés, Carlos Gomez Martin, Marina Magin, Yu-Ming Shen, Renée de Leeuw, Mohamed Bekradda, Eduardo Pennella, Ernesto Wasserman, Viktoriya Stalbovskaya, Jeroen Lammerts van Bueren, Aline Engbers, Andrew Joe, Josep Tabernero
Publikováno v:
Cancer Research. 83:CT156-CT156
The epidermal growth factor receptor (EGFR) is a known driver of cancer growth and the leucine-rich, repeat-containing, G-protein coupled receptor 5 (LGR5) is a transmembrane receptor expressed on cancer stem cells. Petosemtamab is a human, common li
Autor:
Ezra E. Cohen, Jérôme Fayette, Amaury Daste, Caroline Even, Christophe Le Tourneau, Irene Brana, Esma Saada, Elisa Fontana, Lara Iglesias, Shumei Kato, Rocio Garcia-Carbonero, Josep Tabernero, Guillem Argilés, Marina Magin, Yu-Ming Shen, Renée de Leeuw, Mohamed Bekradda, Eduardo Pennella, Ernesto Wasserman, Viktoriya Stalbovskaya, Jeroen Lammerts van Bueren, Lokesh Jain, Andrew Joe, Antoine Hollebecque
Publikováno v:
Cancer Research. 83:CT012-CT012
EGFR is a known driver of cancer growth, and leucine-rich, repeat-containing, G-protein coupled receptor 5 (LGR5) is a transmembrane receptor expressed on cancer stem cells. Petosemtamab is a human, common light chain, IgG1 bispecific antibody with A
Autor:
Emily Butler, Susan Halabi, Alain Ravaud, Evgeny Degtyarev, Robert J. Motzer, Michelle Casey, Paola Aimone, Oliver Sailer, Rui Tang, Daniel J. George, Maria Jose Lechuga, Feng Liu, Viktoriya Stalbovskaya
Publikováno v:
Pharmaceutical Statistics. 20:324-334
The estimand framework requires a precise definition of the clinical question of interest (the estimand) as different ways of accounting for "intercurrent" events post randomization may result in different scientific questions. The initiation of subs
Autor:
Emily Martin, Godwin Yung, Juliane Manitz, Mindy Mo, Rui Sammi Tang, Vincent Haddad, Kaspar Rufibach, Fei Jie, Hannes Buchner, Jyotirmoy Dey, Marie-Laure Casadebaig, Jiangxiu Zhou, Natalia Kan-Dobrosky, Yue Shentu, Viktoriya Stalbovskaya, Evgeny Degtyarev
Publikováno v:
Pharmaceutical statisticsREFERENCES. 21(1)
An addendum of the ICH E9 guideline on Statistical Principles for Clinical Trials was released in November 2019 introducing the estimand framework. This new framework aims to align trial objectives and statistical analyses by requiring a precise defi
Autor:
Alison M. Schram, Koichi Goto, Dong-Wan Kim, Patricia Martin-Romano, Sai-Hong Ignatius Ou, Grainne M. O'Kane, Eileen Mary O'Reilly, Kumiko Umemoto, Michaël Duruisseaux, Cindy Neuzillet, Frans Opdam, Jordi Rodon Ahnert, Misako Nagasaka, Benjamin Adam Weinberg, Teresa Macarulla, Andrew K. Joe, Jim Ford, Viktoriya Stalbovskaya, Ernesto Wasserman, Alexander E. Drilon
Publikováno v:
Journal of Clinical Oncology. 40:105-105
105 Background: NRG1 fusions are rare oncogenic drivers that have been identified in a variety of solid tumors. These proteins bind HER3, leading to HER2/HER3 heterodimerization and oncogenic transformation. Zenocutuzumab (MCLA-128; Zeno) is a Biclon
Publikováno v:
Pharmaceutical statisticsREFERENCES. 19(5)
Autor:
Antoine Hollebecque, Irene Brana, Lara Iglesias, Caroline Even, Kato Shumei, Marc Díez García, Mateo Bover, Patricia Martin-Romano, Rocio Garcia-Carbonero, Guillen Argilés, Josep Tabernero, Rajan Khanna, Viktoriya Stalbovskaya, Jeroen Lammerts van Bueren, Kees Bol, Mohamed Bekradda, Andrew Joe, Ernesto Wasserman, Ezra E.W. Cohen
Publikováno v:
Molecular Cancer Therapeutics. 20:P185-P185
In the expansion part of an ongoing phase 1 study, MCLA-158 is being investigated at the recommended phase 2 dose (RP2D) in patients (pts) with advanced solid tumors, including head and neck squamous cell carcinoma (HNSCC). Epidermal growth factor re
Autor:
Benjamin A. Weinberg, Alison M. Schram, Christelle De La Fouchardiere, Jordi Rodon, Sai-Hong Ignatius Ou, Dong Wan Kim, Teresa Macarulla, Viktoriya Stalbovskaya, Misako Nagasaka, Patricia Martin-Romano, Ernesto Wasserman, Kumiko Umemoto, Eileen M. O'Reilly, Michael Duruisseaux, Grainne M. O'Kane, Cindy Neuzillet, Koichi Goto, Alexander Drilon, James M. Ford, Andrew K. Joe
Publikováno v:
Journal of Clinical Oncology. 39:3003-3003
3003 Background: NRG1 fusion proteins are oncogenic drivers in pancreas cancer and other solid tumors. They bind HER3, leading to HER2/HER3 heterodimerization and oncogenic transformation. The activity of zenocutuzumab (MCLA-128; zeno), a bispecific